We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
+1.9%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$3.17M
AUM Growth
+$561K
Cap. Flow
+$147M
Cap. Flow %
4,647.33%
Top 10 Hldgs %
63.1%
Holding
323
New
68
Increased
74
Reduced
74
Closed
84

Top Buys

Rank Stock Value
1
PFE icon
Pfizer
PFE
+$37.9M
2
ACAD icon
Acadia Pharmaceuticals
ACAD
+$24.5M
3
MRK icon
Merck
MRK
+$12.3M
4
GILD icon
Gilead Sciences
GILD
+$11.7M
5
ACHN
Achillion Pharmaceuticals
ACHN
+$11.6M

Top Sells

Rank Stock Value
1
LRMR icon
Larimar Therapeutics
LRMR
+$4.64M
2
OCUL icon
Ocular Therapeutix
OCUL
+$3.33M
3
ACGN
Aceragen Inc
ACGN
+$2.48M
4
ASPX
AUSPEX PHARMACEUTICALS INC COM STK (DE)
ASPX
+$2.06M
5
PRQR icon
ProQR Therapeutics
PRQR
+$1.95M

Sector Composition

Rank Sector Weight
1 Healthcare 9.16%
2 Energy 0.42%
3 Industrials 0.14%
4 Consumer Staples 0.11%
5 Technology 0.09%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ADVM
51
DELISTED
Adverum Biotechnologies
ADVM
$7.71K 0.24%
14,280
+9,280
+186% +$3.58M
BLCM
52
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
$7.64K 0.24%
+33,152
New +$7.11M
GILD icon
53
CALL
Gilead Sciences
GILD
$165B
$7.51K 0.24%
797
-1,491
-65% -$154K
IONS icon
54
CALL
Ionis Pharmaceuticals
IONS
$9.12B
$7.46K 0.24%
1,209
+829
+218% +$40.9K
ALKS icon
55
PUT
Alkermes
ALKS
$8.22B
$7.36K 0.23%
1,256
+542
+76% +$27.6K
MDVN
56
CALL
DELISTED
MEDIVATION, INC.
MDVN
$7.02K 0.22%
1,410
-2,166
-61% -$113K
ALNY icon
57
CALL
Alnylam Pharmaceuticals
ALNY
$38.5B
$6.85K 0.22%
706
-1,649
-70% -$153K
A icon
58
Agilent Technologies
A
$39.8B
$6.75K 0.21%
+165,008
New +$6.66M
COV
59
DELISTED
COVIDIEN PLC COM SHS NEW (IRELAND)
COV
$6.7K 0.21%
65,537
-1,215
-2% -$117K
DERM
60
DELISTED
Dermira, Inc.
DERM
$6.38K 0.2%
+352,088
New +$5.88M
MNKD icon
61
CALL
MannKind Corp
MNKD
$1.19B
$5.98K 0.19%
2,294
-4,394
-66% -$124K
CEMP
62
CALL
DELISTED
Cempra, Inc.
CEMP
$5.96K 0.19%
2,536
+1,398
+123% +$20.9K
RGLS
63
DELISTED
Regulus Therapeutics
RGLS
$5.65K 0.18%
+2,936
New +$5.22M
PRQR icon
64
ProQR Therapeutics
PRQR
$246M
$5.48K 0.17%
253,083
-128,166
-34% -$1.95M
MBOT icon
65
Microbot Medical
MBOT
$113M
$5.44K 0.17%
3,577
+598
+20% +$1.09M
RMTI icon
66
PUT
Rockwell Medical
RMTI
$26.8M
$5.36K 0.17%
47
– –
CDMO
67
DELISTED
Avid Bioservices, Inc. Common Stock
CDMO
$5.2K 0.16%
+33,971
New +$342K
ABBV icon
68
PUT
AbbVie
ABBV
$470B
$5.05K 0.16%
+772
New +$48.7K
THOR
69
CALL
DELISTED
THORATEC CORPORATION
THOR
$4.92K 0.16%
+1,515
New +$44.1K
CEMP
70
PUT
DELISTED
Cempra, Inc.
CEMP
$4.89K 0.15%
2,082
+1,016
+95% +$15.2K
PRGO icon
71
CALL
Perrigo
PRGO
$1.43B
$4.8K 0.15%
+287
New +$44.9K
DYAX
72
CALL
DELISTED
DYAX CORPORATION
DYAX
$4.77K 0.15%
3,394
+2,522
+289% +$31.6K
DHR icon
73
Danaher
DHR
$142B
$4.72K 0.15%
+81,910
New +$4.44M
AMT icon
74
CALL
American Tower
AMT
$81.6B
$4.57K 0.14%
462
+169
+58% +$16.6K
MNKD icon
75
MannKind Corp
MNKD
$1.19B
$4.49K 0.14%
172,150
+55,166
+47% +$1.56M
1 2
3
4 5

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
CTC
Corundum Trust Company Sioux Falls, South Dakota $43.8M AUM 20.07% 1-Year Est. Return

Sabby Management's Q4 2014 Portfolio in Review

As of Q4 2014, Sabby Management held 323 positions worth $3.17M, up 22% from $2.6M the previous quarter. Its ten largest holdings account for 63% of the portfolio.

Sabby Management deployed $147M of net new capital in Q4 2014, opening 68 new positions and adding to 74 existing holdings. Its largest new stake was Pfizer: 1,322,658 shares worth $39.1K.

By sector, the portfolio is most concentrated in Healthcare at 9.2% of assets, up from 6.3% a quarter earlier, followed by Energy and Industrials.

On the sell side, the largest reduction was Larimar Therapeutics, an estimated $4.64M trimmed.

  • Sabby Management's largest Q4 2014 buy was Pfizer: 1,322,658 shares worth $39.1K.
  • Sabby Management added most to Achillion Pharmaceuticals in Q4 2014, an estimated $11.6M increase.
  • Sabby Management's biggest Q4 2014 reduction was Larimar Therapeutics, cutting an estimated $4.64M.
  • Sabby Management fully exited Aceragen Inc in Q4 2014, selling an estimated $2.48M.
  • Sabby Management's ten largest holdings make up 63% of its $3.17M portfolio in Q4 2014.
  • Sabby Management opened 68 new positions and closed 84 in Q4 2014.
  • Sabby Management's portfolio value rose 22% quarter-over-quarter to $3.17M.

Based on Sabby Management's 13F filing for Q4 2014, filed 17 Feb 2015.